Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxifloxacin vs ofloxacin eye drops for acute bacterial conjunctivitis
CTR20171432Phase 3Active
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Mar 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of moxifloxacin in bacterial conjunctivitis (BC), sponsored by Yangtze River Pharmaceutical Group. Started Mar 2018; status: active.
02
Drugs
moxifloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on CTR20171432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171432.